About
Ben is a Partner at F-Prime Capital and has worked in pharmaceuticals and life science for over twenty years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from the assay stage into phase II clinical studies and was co-inventor on 15 product patents. Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and two companies where he was a company founder, Orchard Therapeutics and Dimension Therapeutics. He currently serves on the Board of Directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Symbiomix Pharmaceuticals,
Position in the VCSift Database
- • 2 investors at Idrx are tracked.
- • 927 investors hold the Co-Founder and CEO role in VCSift. Ben Auspitz is one of them.
- • 2,293 investors are based in Boston, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Boston, US
Contact Information
Find more investors like Ben
Search Investors